HomeCompareKRMCF vs ABBV

KRMCF vs ABBV: Dividend Comparison 2026

KRMCF yields 454.55% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KRMCF wins by $29618.94M in total portfolio value
10 years
KRMCF
KRMCF
● Live price
454.55%
Share price
$0.44
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29619.04M
Annual income
$20,672,526,630.46
Full KRMCF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — KRMCF vs ABBV

📍 KRMCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKRMCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KRMCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KRMCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KRMCF
Annual income on $10K today (after 15% tax)
$38,636.36/yr
After 10yr DRIP, annual income (after tax)
$17,571,647,635.89/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, KRMCF beats the other by $17,571,626,579.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KRMCF + ABBV for your $10,000?

KRMCF: 50%ABBV: 50%
100% ABBV50/50100% KRMCF
Portfolio after 10yr
$14809.57M
Annual income
$10,336,275,701.11/yr
Blended yield
69.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

KRMCF
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KRMCF buys
0
ABBV buys
0
No recent congressional trades found for KRMCF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKRMCFABBV
Forward yield454.55%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$29619.04M$102.3K
Annual income after 10y$20,672,526,630.46$24,771.77
Total dividends collected$28823.07M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KRMCF vs ABBV ($10,000, DRIP)

YearKRMCF PortfolioKRMCF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$56,155$45,454.55$11,550$430.00+$44.6KKRMCF
2$298,635$238,549.47$13,472$627.96+$285.2KKRMCF
3$1,505,172$1,185,632.86$15,906$926.08+$1.49MKRMCF
4$7,195,392$5,584,858.27$19,071$1,382.55+$7.18MKRMCF
5$32,650,572$24,951,502.07$23,302$2,095.81+$32.63MKRMCF
6$140,751,597$105,815,484.50$29,150$3,237.93+$140.72MKRMCF
7$576,916,626$426,312,417.48$37,536$5,121.41+$576.88MKRMCF
8$2,250,367,516$1,633,066,726.35$50,079$8,338.38+$2250.32MKRMCF
9$8,361,231,346$5,953,338,104.06$69,753$14,065.80+$8361.16MKRMCF
10$29,619,044,171$20,672,526,630.46$102,337$24,771.77+$29618.94MKRMCF

KRMCF vs ABBV: Complete Analysis 2026

KRMCFStock

KRM22 Plc, together with its subsidiaries, develops and sells risk management software to the financial services industry in the United Kingdom, Europe, the United States, and internationally. The company offers Risk Cockpit, which shows enterprise risk profile in real time; Regulatory Navigator that brings out-the-box regulatory functionality covering market abuse, SM&CR, and financial crime; and Market Surveillance that offers analytics and contextual market surveillance tools to help capital markets firms identify and manage the potential risks of market abuse, fraud, and operational breaches. It also provides Individual Accountability Regime, which allows financial institutions to manage accountability throughout the firm; Digital Client Onboarding that provides capital market firms with the tools to make client onboarding; and Regulatory Reporting that enables capital market firms to comply with its regulatory reporting obligations across multiple jurisdictions. In addition, the company offers Enhanced Due Diligence, which enables firms to understand online reputational risks and evidence compliance; Regulatory training that helps regulated firms address their mandatory training requirements; Post-Trade Risk – Stress, which scales the type and amount of risk calculations performed against various limits and risk slides; and Post-Trade Risk – VaR that provides the unique view of multiple VaR calculations across the whole portfolio in a single place. Further, it provides At-Trade Risk, which offers P&L and exchange margin for clearing houses and members, traders, brokers, and other financial institutions that make decisions based on the management of risk; and Pre-Trade Risk, which helps combat time consuming and error prone processes by maintaining pre-trade limits in one centralized application. The company was founded in 2017 and is headquartered in London, the United Kingdom.

Full KRMCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this KRMCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KRMCF vs SCHDKRMCF vs JEPIKRMCF vs OKRMCF vs KOKRMCF vs MAINKRMCF vs JNJKRMCF vs MRKKRMCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.